Abstract: A processor-implemented method includes obtaining a first motion matrix corresponding to an extended reality (XR) system and a second motion matrix based on a conversion coefficient from an XR system coordinate system into a rolling shutter (RS) camera coordinate system, and projecting an RS color image of a current frame onto a global shutter (GS) color image coordinate system based on the second motion matrix and generating a GS color image of the current frame, wherein the second motion matrix is a motion matrix of a timestamp of a depth image captured by a GS camera corresponding to a timestamp of a first scanline of an RS color image captured by the GS camera.

Abstract: A method includes obtaining a first image, where the first image includes an RGB image and a first depth image as components of the first image, obtaining at least two image regions by processing the first image through an artificial intelligence (AI) network based on gaze point information, and obtaining a second depth image based on the at least two image regions, where, in the at least two image regions, image qualities of respective image regions are different, and a resolution of the first depth image is lower than a resolution of the second depth image.

Abstract: A method with image processing includes: determining a feature map of an image; determining a spatial position weight of pixel points of the feature map; determining a corrected feature map by correcting the feature map based on the spatial position weight of the pixel points; and determining a key point based on the corrected feature map.

Abstract: A processor-implemented method includes obtaining a first motion matrix corresponding to an extended reality (XR) system and a second motion matrix based on a conversion coefficient from an XR system coordinate system into a rolling shutter (RS) camera coordinate system, and projecting an RS color image of a current frame onto a global shutter (GS) color image coordinate system based on the second motion matrix and generating a GS color image of the current frame, wherein the second motion matrix is a motion matrix of a timestamp of a depth image captured by a GS camera corresponding to a timestamp of a first scanline of an RS color image captured by the GS camera.

Abstract: An apparatus and method with depth estimation are disclosed. The method includes calculating a first reliability of each of a plurality of time of flight (ToF) pixels of a ToF image; and generating, based on the first reliabilities, a depth map of a scene based on a left image and a right image and selectively based on the ToF image.

Abstract: An apparatus and method of estimating an object posture are provided. A method includes determining key point information in an image to be processed, determining modified key point information based on a key point feature map corresponding to the key point information, and estimating an object posture of an object in the image to be processed, based on the modified key point information.

Abstract: A processor-implement method with image processing includes: generating a feature map of a first image and detecting a target region in the first image based on the feature map; correcting the detected target region; and processing an object corresponding to the target region, based on the corrected target region.

Abstract: A method with image processing includes: determining a feature map of an image; determining a spatial position weight of pixel points of the feature map; determining a corrected feature map by correcting the feature map based on the spatial position weight of the pixel points; and determining a key point based on the corrected feature map.

Abstract: The invention relates to application of 4,4?-diphenylmethane-bis(methyl) carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients.

Abstract: The invention relates to application of 4,4?-diphenylmethane-bis(methyl) carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating diabetic complications, mainly referring to diabetic nephropathy, and the pharmaceutical composition comprises one or both of calycosin and calycosin-7-O-?-D-glucoside as 0.1˜99.5% by weight based on the total weight of the composition, and the conventional drug carrier. The pharmaceutical composition could significantly prevent and treat diabetic nephropathy, with the convenience of quality control and administration, which provides a new drug candidate for patients with diabetic nephropathy.

Abstract: The invention relates to a pharmaceutical composition for diabetic nephropathy and its preparation, and the application in preparing of medicine for diabetic nephropathy. The pharmaceutical composition is made up of at least one of 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin as active ingredient, and the weight percentage of active ingredient is 0.1-99.5%. Moreover, the pharmaceutical composition is mainly used for the prevention and cure of diabetic nephropathy. For the abundant material, remarkable effect on prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients.

Abstract: The invention relates to application of 4,4?-diphenylmethane-bis(methyl)carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients.